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Abstract  
 
Background 
Developing and managing measures of Quality of Life (QoL) requires attention to 
a range of broader concepts, in addition to meeting validation requirements.   
 
Objectives 
The aim of this review is to describe development and experience in Cardiff 
of these concepts and to inform users of Cardiff quality of life tools of 
aspects of their origin, for the benefit of developers of novel QoL measures or 
other patient reported outcome measures.   
 
Methods 
Publications from the Cardiff team over the last three decades are used to 
illustrate descriptions of concepts involved in developing and managing 
QoL measures. 
 
Results 
The concepts are grouped into three main themes: A) Design of tools: 
measurement ability turns ideas into science, QoL measurement based on 
patient experience, the need for tools to be clinically practical and useful with 
meaningful scores, different ages need tailored tools. B) Practical management of 
tools: enabling ease of access, maintenance of single version, translation validity, 
enabling access to post publication experience and further validation. C) 
Promoting wider understanding of QoL: examples include educate thinking with 
disease severity definition; heighten awareness of broader burden, family impact 
and the time dimension.  
 
Conclusion 
The development and management of QoL and other outcome measures 
involves attention to a wide range of other issues, in addition to meeting 
validation requirements. 
 
 
 
Key words  
Quality of Life, concepts, measurement development, design, validation, skin 
disease burden 
 
 
 Introduction 
 
A prime focus in quality of life (QoL) measurement is on the appropriate 
validation of new measures.1,2,3  But questionnaire validation takes place in a 
much broader framework of concept development and tool management, 
involving wider issues that are seldom discussed.  An understanding of the 
motivations behind the creation of a QoL measurement tool and how concepts 
around QoL measurement have developed provides a fuller appreciation of a 
QoL measure.   
 
The aim of this review is to describe the development of the conceptual 
framework within which some commonly used QoL measures have been created, 
the motivations behind their creation and the strategies used to manage these 
tools.  The experience of the Cardiff team is described.  This background 
information provides novel transparency and also gives an ǲinsideǳ perspective: 
this may be of interest to those using such measures and be of value in informing 
developers of new tools. Fig 1(a) depicts the basic outline of the creation of a 
new QoL measure: the surrounding broader framework and concepts, 
encompassing validation, are depicted in Fig 1(b). Some of the concepts 
described are seldom discussed but may be crucial in determining whether a tool 
is actually used.  Others are either closely related to or are an integral part of 
validation of a new measure, but are presented here within this broader 
framework. 
 
Insert Figure 1(1a and 1b) here. 
 
Design of QoL measurement tools 
 
Once you can measure it, it can become a science 
 
Years ago there were detailed descriptions4,5  of the impact of skin diseases on 
QoL. But apart from stating that this impact existed, there was little more that 
could be done.  In the scientific world, things that cannot be measured are often 
accorded little importance: to make people properly aware of this QoL impact 
and to consider what can be done to positively influence it, it was necessary to be 
able to measure it and to turn a descriptive aspect of clinical medicine into a 
science. 
 
Encouraged by an editorial6 and influenced to measure all aspects of skin,7 we 
developed the first disease specific QoL measure in dermatology, the Psoriasis 
Disability Index.8,9  We interviewed large numbers of patients with psoriasis, 
asked them what impact it was having on their lives, and distilled the answers 
into a series of questions.  Crucially the answer to each question was scored and 
then summed to give an overall score.  This was then used to provide the first 
demonstration that, overall, QoL was improved by inpatient therapy for 
psoriasis.8   That study also identified some patients whose QoL was worse after 
inpatient treatment: this information could have been crucial in informing 
clinical decisions over those patients, illustrating the powerful clinical potential 
of being able to measure QoL.  This experience encouraged us to create another 
disease specific measure, the Cardiff Acne Disability Index.10,11 
 
 
Measurement of QoL solely based on patient experience 
 
Clinicians may believe they have more insight into a disease and its impact than 
those affected.  After all, clinicians see large numbers of patients with a 
particular condition, understand about its impact and so could have a wider 
knowledge of the disease than any individual patient.  Some measures have been 
based on a mixture of clinician opinion, literature review and patient input. 12  
Information from these other sources may be important. However, for the 
measures we have created the question content has always been based solely on 
the actual experiences of patients.  One of the reasons that the DLQI has been so 
widely accepted worldwide may be because of this question basis.13   The 
information on which a measure is based is an important additional validation 
characteristic not included in some reviews.2 
 
 
The need to make measurement of QoL clinically practical 
 
Disease specific measures such as the PDI or CADI could be created for every 
skin disease.  However this would result in a confusing array of measures for the  
large number of different skin diseases, impractical for any clinician to use 
routinely.  The basic aspects of peopleǯs lives affected by skin disease are largely 
the same, though with different emphases.  This raised the prospect of 
developing a single questionnaire that could be used in patients with any skin 
disease, a crucial aspect of making QoL measurement practical in the clinic. 
 
By the ͳͻͺͲǯs there were several generic QoL or Health-Related QoL (HRQOL 
measures) designed for use across all of medicine, such as the Sickness Impact 
Profile and the Short Form-36.  Many were long and so unsuitable for routine use 
in a busy clinic, but could be used for research to measure QoL in dermatology. 14   
However if QoL measurement was ever going to be carried out routinely in a 
clinic, it was essential that the measure be short, easy to understand, able to be 
completed unaided and have a simple method of scoring.   
 These practical considerations were at the heart of the design of the 
Dermatology Life Quality Index (DLQI).15  This measure was used extensively as 
a patient reported outcome measure in clinical research16 before it was 
eventually accepted as a routine clinical measure. 
 
Efforts to produce the DLQI were also driven by a desire to be the first to create 
such a specialty specific measure.  It was several years after first presentation17 
that other measures with the same aim were published.18,19  The novelty of the 
concept of measuring QoL across skin disease was emphasised by its initial 
publication rejection.20 
 
 
Adding ǲusefulnessǳ to measures: score meaning, conversion of data, e-
usage. 
 
For most HRQoL measures there is no guidance over what the scores mean 
clinically, or how to interpret score change.  These measures may be used in a 
research setting, but, without meaning, they are of little value clinically. 
 
The creation of validated score meaning bands for the DLQI was a critical step:21  
for example a score from 11 to 20 means the skin disease Ǯis having a very large 
effect on the quality of life of the patientǯ.  This transformed the DLQI from being 
confined to research to being a tool that a clinician could actually use and 
understand.22   The knowledge of what constitutes a Minimally Clinically 
Important Difference (for the DLQI a score change of four)23  also allows 
clinicians and researchers to interpret the clinical meaning of a change in score. 
 
A more recent ǲadded usefulnessǳ study has demonstrated how DLQI scores of a 
population of subjects can be converted to EQ5D utility scores.24   This has 
potential for enhancing the value of existing large databases of DLQI information.   
 
HRQoL measures are frequently administered ǲon screenǯ on the unproven 
assumption that subjects will respond to a questionnaire administered via tablet 
or smart phone in the same way as on paper.   The validity of administering the 
DLQI in an app has now been demonstrated,25  providing reassurance to users of 
the DLQI that this mode of application will not invalidate results. 
 
 
Addressing the needs of different ages 
 
Most QoL measures have been developed for adults, with consideration given 
only later to infants, children, teenagers and the elderly.  The lives of people at 
these ages are obviously very different and so separate measures are needed.  
The issues are complex: surrogate measures have to be used for infants, the lives 
of children are very different at different ages, and the varying ages of 
development of teenagers need to be taken into account in tool design: this has 
been highlighted comparing the use of the DLQI and CDLQI in 16-18 year olds.26 
 
The mode of administration of a questionnaire may have an impact on its use 
and usefulness.  The CDLQI was made more fun for younger children by adding 
cartoons to the standard text:27  there is great potential for further such 
development with e-delivery.   
 
 
Practical management of QoL tools 
 
The need to ensure ease of access: constantly updated website 
 
Instant open access is essential for a measure to be useful to clinicians or 
researchers.  Since 1995, the Cardiff University Dermatology Department 
website has provided all of the QoL measures in full, along with all approved 
translations, scoring information and references.28 If online information is 
complemented by rapid response communication with the measure originators, 
users are able to take fully informed decisions about which measures are best for 
their use. 
 
 
The need to maintain a single version of a measure 
 
The wording of any questionnaire designed to measure QoL must always be 
exactly the same. Validity, comparability of scores and reliability are all annulled 
if the words change.  The protection of copyright law29 is critical in maintaining 
the integrity and value of a questionnaire, while not inhibiting the clinical use of 
a measure.  Hundreds of requests to alter DLQI wording have been refused: the 
cumulative effect would have been to cause confusion and rejection amongst 
potential users. The reality for clinicians is that choice over QoL measures leads 
to confusion: one strategy therefore is to try to add ǲusefulnessǳ to measures 
(despite any faults) rather than producing different versions. 
 
 
The need to ensure translation validity, a single validated translation and 
cultural appropriateness 
 
It is unusual for a single one-way translation to be totally accurate: subtle 
differences between languages, mistakes and differences of opinion are common.  
A validated process is needed with a minimum of two independent translators 
creating one forward translation, then coming together to reach an agreed 
translation.  Then third and fourth independent translators back translate to the 
original language to be reviewed by the original authors.  This nearly always 
reveals inconsistencies: the process is repeated until the translation is as 
accurate as possible.  All translations of the Cardiff University measures have 
gone through this process before being placed online.28   
 
The translation process results in an almost exact language translation.  
However there is also a need for cultural adaptation.  This is to ensure that 
questions are relevant, or modified to ensure appropriateness in the culture of 
the country of use. This involves testing the questionnaire with local subjects and 
incorporating feedback.  Even where validated translation and cultural 
adaptation has been carried out, this does not necessarily ensure that scores will 
have exactly the same meaning between different countries.30   This assumption 
is often made, especially in multinational studies, and is an unresolved issue of 
relevance to all HRQoL measures. 
 
If more than one centre independently translates a measure there is the 
likelihood that two version of the measure, probably with slight differences of 
meaning, could circulate causing great confusion.  The likelihood of this can be 
reduced by having the validated translation for each country accessible online 
and by not giving permission for second translations.  Where errors are pointed 
out they can be checked and corrected where appropriate.  
 
Summarising experience with tools, for easy access to validation 
information 
 
It is helpful if QoL instrument developers summarise and report on the later 
published experience of their use, though this seldom happens. In reviews parallel to the ǲPost-Marketingǳ surveys of new therapies, we have reported on 
10-20 years experience of the PDI,31 DLQI,16,32 CDLQI,33 IDQoL34 and DFI.35  
These summaries bring together many aspects of validation of these measures 
that would otherwise remain scattered and unidentified in the literature. They 
also highlight aspects of validation that still need to be addressed. 
 
There are many anecdotal reports of the use of QoL measures in routine clinical 
practice but hardly any publications36 describing or assessing this use.  The 
EADV Task Force on Quality of Life has given an expert opinion statement 
describing the potential benefits of routine use of QoL measures.37 
 
 
Promoting wider understanding of QoL and its measurement 
 There are ways in which developers of QoL measures may enhance wider 
understanding of the use of these tools.  Examples include the Rule of Tens, a 
focus on family impact and an emphasis on the long-term effects of skin disease on peopleǯs lives. 
 
Creating a simple definition to educate thinking about QoL: 
The Rule of Tens 
 
The Rule of Tens (Fig 2) was the first proposal to incorporate a QoL measure in a 
disease severity definition.38   There were several underlying motivations. The ǲRuleǳ aimed to alter thinking about QoL, demonstrating that it is of equal 
importance in assessing disease severity as traditional sign based measures.  Its 
acceptance would lead to more familiarity with and publicity for the DLQI. The 
Rule would educate clinicians that DLQI scores mean something and that Ǯover ͳͲǯ means Ǯa very large effect on QoLǯ.21   The Rule was also proposed at a time 
when the National Institute for Clinical Excellence in the UK were initially 
considering a much higher cut off DLQI score threshold for use of biologics in 
psoriasis: the Rule contributed to achieving the objective of lowering this 
threshold. Many national guidelines now incorporate the Rule of Tens or 
variations on this Rule, thereby achieving the original aims.39 
 
Insert Figure 2 here 
 
Heightening awareness of the broader burden of skin disease: the family 
impact 
 
Attention to the impact of skin disease on QoL inevitably focussed first on the 
patient experience.14,15,18   However skin disease also impacts on partners or 
other family members.  The term ǮThe Greater Patientǳ was proposed to 
encourage awareness of this:40  it describes the immediate family unit 
surrounding the patient, whose lives may also be disrupted by the disease (Fig 
3). 
 
Most obviously, a child with atopic dermatitis will have parents whose lives are 
also disrupted.41   As little attention is paid to a problem unless it can be 
measured, the Dermatitis Family Impact questionnaire42 was created to measure 
the impact of childhood atopic dermatitis on the QoL of other family members.  
The similar impact of psoriasis43 can now be captured by the Psoriasis Family 
Impact-1444 and the Family Dermatology Life Quality Index (FDLQI)45,46  can be 
used to assess the impact across any skin disease. 
 
This partner and family impact of disease occurs across the whole of medicine.47 
As there was no generic questionnaire (equivalent to the EQ5D or SF-36) for 
families, a generic measure was developed, derived from 26 specialties, the 
Family Reported Outcome Measure (FROM-16).48  By allowing the impact on 
families to be measured, further research is encouraged, hopefully eventually 
resulting in evidence based methods to mitigate the secondary impact on the 
family. 
 
 
Understanding the broader burden of skin disease: the time dimension 
 
In a clinic, what seems to matter most is to understand how a disease is affecting a patientǯs life now, today, so that appropriate action can be taken.  Nearly all 
QoL measures are designed to measure that current impact.  But having a skin 
disease can influence Major Life Changing Decisions (MLCD)49  and so the life 
impact can echo down the years, while chronic skin disease causes cumulative 
life course impairment.50  The term ǲthe Three Dimensions of QoL impactǳ (Now, 
Family and Long-term)51 was suggested to emphasise the importance of this 
temporal aspect of QoL (Fig 3): a template to record MLCDs52 has also been 
developed. 
 
Insert Figure 3 here 
 
Conclusion 
 
This review describes a series of concepts developed over three decades while 
researching QoL in dermatology.  Attention to some of these broader issues, in 
addition to fully validating new tools, may be of benefit to developers of novel 
QoL measures or other PROMs. 
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Figures 
 
Figure 1.  
(A) Summary of steps in creation of a new quality of life measure. 
(B) Framework and interconnectivity of concepts described, encompassing 
validation. 
Figure 2. 
The Rule of Tens to describe current severe psoriasis.38 
Figure 3 
The Three Dimensions of QoL impact:51  Now, Family40 and Long-term.  
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